[Current aspects of the therapy with topical calcineurin inhibitors].
Since their approval, topical calcineurin inhibitors have proven to be effective medications in the treatment of atopic eczema. On March 10, 2005, the Food and Drug Administration (FDA) followed the advice of the Pediatric Advisory Council and issued a "black box warning" for the use of Protopic (Tacrolimus) und Elidel (Pimecrolimus). This FDA alert has caused worldwide uncertainty among parents and patients. Several dermatological societies have issued critical position statements. This report reviews the existing information underlying the warning and places it into the context of current knowledge.
Enderlein
E
E
Hautklinik, Heinrich-Heine-Universität Düsseldorf.
Meller
S
S
Rieker
J
J
Ruzicka
T
T
Homey
B
B
D000287:Administration, Topical; D065095:Calcineurin Inhibitors; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects; D004348:Drug Labeling; D005858:Germany; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007258:Informed Consent; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives*; D014481:United States; D014486:United States Food and Drug Administration
D065095:Calcineurin Inhibitors; D003879:Dermatologic Agents; C117268:pimecrolimus; D016559:Tacrolimus